Search

Your search keyword '"Calmy A."' showing total 2,902 results

Search Constraints

Start Over You searched for: Author "Calmy A." Remove constraint Author: "Calmy A."
2,902 results on '"Calmy A."'

Search Results

1. Sustained HIV remission after allogeneic hematopoietic stem cell transplantation with wild-type CCR5 donor cells

2. Infectious disease events in people with HIV receiving kidney transplantation: Analysis of the Swiss HIV Cohort Study and the Swiss Transplant Cohort Study

3. Immune response to the recombinant herpes zoster vaccine in people living with HIV over 50 years of age compared to non-HIV age-/gender-matched controls (SHINGR’HIV): a multicenter, international, non-randomized clinical trial study protocol

4. SARS-CoV-2 cross-sectional serosurvey across three HIV-1 therapeutic clinical trials in Africa

5. Booster-free anti-retroviral therapy for persons living with HIV and multidrug resistance (B-Free): protocol for a multicentre, multistage, randomised, controlled, non-inferiority trial

6. Patient and public involvement in HIV research: a mapping review and development of an online evidence map

7. Transcriptional profile of Mycobacterium tuberculosis infection in people living with HIV

8. Population pharmacokinetics of rilpivirine following oral administration and long-acting intramuscular injection in real-world people with HIV

9. Cohort profile: the Swiss Mother and Child HIV Cohort Study (MoCHiV)

10. Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine: a multicenter prospective observational study in Switzerland

11. GDF15 is dispensable for the insulin-sensitizing effects of chronic exercise

12. Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on antiretroviral therapy: 48-week results of a phase 3, randomised, open-label, non-inferiority trial

13. Study protocol for assessment of the efficacy of calcium dobesilate versus placebo on SARS-CoV-2 viral load in outpatients with COVID-19 (CADOVID study): a randomised, placebo-controlled, double-blind, monocentric phase II trial

14. Costs and acceptability of simplified monitoring in HIV-suppressed patients switching to dual therapy: the SIMPL’HIV open-label, factorial randomised controlled trial

16. Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials

17. Mpox: The alarm went off. Have we gone back to sleep?

18. MOSAIC: A cohort study of human mpox virus disease [version 3; peer review: 2 approved]

20. Viral suppression and retention in HIV care during the postpartum period among women living with HIV: a longitudinal multicenter cohort study

21. Revealing viral and cellular dynamics of HIV-1 at the single-cell level during early treatment periods

22. External validation of the PAGE-B score for HCC risk prediction in people living with HIV/HBV coinfection

23. Mpox in people with advanced HIV infection: a global case series

24. MOSAIC: A cohort study of human mpox virus disease [version 2; peer review: 2 approved]

25. An Automated Literature Review Tool (LiteRev) for Streamlining and Accelerating Research Using Natural Language Processing and Machine Learning: Descriptive Performance Evaluation Study

26. Risks of metabolic syndrome in the ADVANCE and NAMSAL trials

27. Intensified tuberculosis treatment to reduce the mortality of HIV-infected and uninfected patients with tuberculosis meningitis (INTENSE-TBM): study protocol for a phase III randomized controlled trial

28. Membrane estrogen receptor-α contributes to female protection against high-fat diet-induced metabolic disorders

29. Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon

30. Capacity Building in Sub-Saharan Africa as Part of the INTENSE-TBM Project During the COVID-19 Pandemic

31. Dexamethasone exposure in normal‐weight and obese hospitalized COVID‐19 patients: An observational exploratory trial

32. How the COVID-19 Pandemic Alters the Landscapes of the HIV and Tuberculosis Epidemics in South Africa: A Case Study and Future Directions

34. Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses

35. Therapeutic anticoagulation to prevent thrombosis, coagulopathy, and mortality in severe COVID‐19: The Swiss COVID‐HEP randomized clinical trial

36. Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study

38. Dynamics of virological and immunological markers of HIV persistence after allogeneic haematopoietic stem-cell transplantation in the IciStem cohort: a prospective observational cohort study

39. Post-exposure Lopinavir-Ritonavir Prophylaxis versus Surveillance for Individuals Exposed to SARS-CoV-2: The COPEP Pragmatic Open-Label, Cluster Randomized Trial

41. Responses to controlled release potassium fertilisers in agriculture following phosphate mining

44. How mHealth Can Contribute to Improving the Continuum of Care: A Scoping Review Approach to the Case of Human Immunodeficiency Virus in Sub-Saharan Africa

45. SARS-CoV-2 m-RNA Vaccine Response in Immunocompromised Patients: A Monocentric Study Comparing Cancer, People Living with HIV, Hematopoietic Stem Cell Transplant Patients and Lung Transplant Recipients

46. Population pharmacokinetics of rilpivirine following oral administration and long-acting intramuscular injection in real-world people with HIV.

47. Efficacy and Safety of Dolutegravir Plus Emtricitabine vs Combined Antiretroviral Therapy for the Maintenance of HIV Suppression: Results Through Week 144 of the SIMPL'HIV Trial.

48. Patient and public involvement in HIV research: a mapping review and development of an online evidence map.

49. Circulating HBV RNA and Hepatitis B Core–Related Antigen Trajectories in Persons With HIV/HBV Coinfection and Hepatitis B Surface Antigen Loss During Tenofovir Therapy.

Catalog

Books, media, physical & digital resources